reports
- MarketLine Department
Kalobios Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partner...
Summary Marketline's Kalobios Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Kalobios Pharmaceuticals, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive ...
- MarketLine Department
ARIAD Announces Submission of Marketing Authorization Application for ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the submission of a Marketing Authorization Application (MAA) for its investigational oral anaplastic lymphoma kinase (ALK) inhibitor, brigatinib, to the European Medicines Agency (EMA). ARIAD is seeking marketing approval in the European Union of brigatinib in adult patients with anaplastic lymphoma kinase (ALK+) non-small cell lung cancer (NSCLC) who have been previously treated with crizotinib. The U.S. Food and Drug Administration...
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Pr...
STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) (“ARIAD” or the “Company”) relating to the proposed buyout of ARIAD by Takeda Pharmaceutical Company Limited. Under the terms of the agreement, ARIAD shareholders are anticipated to receive $24.00 in cash for each share of ARIAD common sto...
ARIAD PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. ...
WILMINGTON, Del.--(BUSINESS WIRE)-- Rigrodsky & Long, P.A.: Do you own shares of ARIAD Pharmaceuticals, Inc. (NASDAQ GS: ARIA)? Did you purchase any of your shares prior to January 9, 2017? Do you think the proposed buyout price is too low? Do you want to discuss your rights? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of ARIAD Pharmaceuticals, Inc. (“ARIAD” or the “Company”) (NASDAQ...
ARIAD Enters into Definitive Agreement to Be Acquired by Takeda for $5...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ARIAD Pharmaceuticals (NASDAQ:ARIA) (“ARIAD”) today announced it has entered into a definitive agreement to be acquired by Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) under which Takeda will acquire all of the outstanding shares in ARIAD for $24.00 per share in cash, or a total enterprise value of approximately $5.2 billion, representing a premium of approximately 75 percent over ARIAD’s closing price on January 6, 2017. Under the terms of the agreement, ARIAD stockholders ...
ARIAD to Present at the 35th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), a rare cancer-focused innovative biotechnology company, today announced that it will present at the 35th Annual J.P. Morgan Healthcare Conference. Paris Panayiotopoulos, president and chief executive officer, will provide an overview of the Company’s business on Monday, January 9, 2017 at 4:30 p.m. (PT). The ARIAD presentation will be webcast live and can be accessed by visiting the investor relations section of the Company’s website at htt...
ARIAD’s Investigational Medicine Brigatinib Demonstrated 15.6 Month...
CAMBRIDGE, Mass. & VIENNA--(BUSINESS WIRE)-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), a rare cancer-focused innovative biotechnology company, today announced clinical data on brigatinib, its investigational anaplastic lymphoma kinase (ALK) inhibitor, from the pivotal ALTA trial in ALK-positive (ALK+) non-small cell lung cancer (NSCLC) patients who had experienced disease progression on crizotinib therapy. As of May 31, 2016, the data show that of patients on the 180-mg regimen with a median follow-up of 11 months, 55 percent...
ARIAD Announces Data Presentations at American Society of Hematology M...
CAMBRIDGE, Mass. & SAN DIEGO--(BUSINESS WIRE)-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the results of clinical and translational studies on Iclusig® (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). These data were featured in an oral and two poster presentations at the 57th Annual Meeting of the American Society of Hematology (ASH) taking place in ...
ARIAD Presents Updated Brigatinib Data with 18.4 Months Median Intracr...
CAMBRIDGE, Mass. & VIENNA--(BUSINESS WIRE)-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), a rare cancer-focused innovative biotechnology company, today announced clinical data on brigatinib, its investigational anaplastic lymphoma kinase (ALK) inhibitor, from the ongoing Phase 1/2 and pivotal ALTA trials in patients with ALK-positive (ALK+) non-small cell lung cancer (NSCLC) and intracranial central nervous system (CNS) metastases. These data, being presented today at the International Association for the Study of Lung Cancer (I...
ARIAD to Host Webcast and Conference Call on Brigatinib Data Presentat...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA), a rare cancer-focused innovative biotechnology company, today announced a conference call and webcast to discuss the clinical data presented on brigatinib, the Company’s investigational anaplastic lymphoma kinase (ALK) inhibitor, at the International Association for the Study of Lung Cancer (IASLC) 17th World Conference on Lung Cancer (WCLC). Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer of ARIAD will ...
ARIAD Announces FDA Full Approval and Label Update for Iclusig® (pona...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the U.S. Food and Drug Administration (FDA) has granted Iclusig® (ponatinib) full approval for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) for whom no other tyrosine kinase inhibitor (TKI) therapy is indicated; and for the treatment of adult patients with T315I-positive CML (chronic p...
ARIAD Announces Data Presentations at the World Conference on Lung Can...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), a rare cancer-focused innovative biotechnology company, today announced that clinical data on brigatinib, its investigational anaplastic lymphoma kinase (ALK) inhibitor, will be presented at the International Association for the Study of Lung Cancer (IASLC) 17th World Conference on Lung Cancer (WCLC) being held in Vienna, December 4 to 7, 2016. “We are excited that updated data from the ALTA trial on brigatinib in patients with ALK-positive...
ARIAD Announces Launch of Inaugural ALK+ Day During Lung Cancer Awaren...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- In recognition of this month’s Lung Cancer Awareness Month, ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced the launch of an inaugural awareness day for anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC) patients and their care partners. The awareness day is the first of its kind to specifically focus on ALK+ NSCLC and will be held on November 15th and subsequently on the third Tuesday of each November. This Smart News Release features multimedia. View ...
ARIAD Announces Phase 1/2 Trial Data on Investigational Drug Brigatini...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced clinical data on its investigational anaplastic lymphoma kinase (ALK) inhibitor, brigatinib, were published in The Lancet Oncology (Gettinger, S.; ed al. The Lancet Onc. 2016, DOI: 10.1016/S1470-2045(16)30392-8 Published 8 November 2016). ARIAD has submitted a New Drug Application (NDA) for brigatinib to the U.S. Food and Drug Administration (FDA), seeking U.S. marketing approval for patients with metastatic ALK-positive (ALK+) non-sm...
ARIAD Reports Third Quarter 2016 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the third quarter and first nine months of 2016. The Company also provided an update on corporate developments and reaffirmed 2016 financial guidance. “During the third quarter, ARIAD achieved several important milestones that further our commitment as a small, research-based biotechnology company to patients with rare cancers, including those with no other targeted treatment options available,” said Pari...
ARIAD to Present at the Jefferies 2016 London Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Jefferies 2016 London Healthcare Conference. Company management will provide an overview of the Company’s business on Wednesday, November 16, 2016 at 4:40 p.m. (GMT). The ARIAD presentation will be webcast live and can be accessed by visiting the investor relations section of the Company's website at http://www.ariad.com/investor. A replay of the presentation will also be available and archived on the ...
ARIAD to Webcast Conference Call on Third Quarter 2016 Financial Resul...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its third quarter 2016 financial results on Monday, November 7, 2016, before the market opens. Following the announcement, at 8:30 a.m. Eastern Time, company management will host a conference call and webcast discussion of the results and provide a general corporate update. The live webcast can be accessed by visiting the investor relations section of the Company’s website at http://investor.ariad.com. The...
ARIAD Announces U.S. Food and Drug Administration Acceptance of NDA Fi...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ARIAD’s investigational oral anaplastic lymphoma kinase (ALK) inhibitor, brigatinib, in patients with metastatic ALK-positive (ALK+) non-small cell lung cancer (NSCLC) who have progressed on crizotinib. The FDA granted ARIAD’s request for Priority Review and has set an action date of April 29, 2017 under the Prescription Drug Us...
SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Ariad...
LOS ANGELES--(BUSINESS WIRE)-- Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Ariad Pharmaceuticals Inc. (“Ariad” or the “Company”) (Nasdaq: ARIA) concerning possible violations of federal securities laws. If you purchased or otherwise acquired Ariad shares and would like more information regarding the investigation, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.